ABBV vs QCOM: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and QUALCOMM Incorporated — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
QUALCOMM Incorporated · Technology
$201.97
-21.1% upside to fair value
Med Conviction
Grade D
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(-1.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
QCOM |
| Current Price |
$261.70 |
$201.97 |
| Fair Value Estimate |
$259.04 |
$159.42 |
| Upside to Fair Value |
-1.0%
|
-21.1%
|
| Market Cap |
$462.4B |
$212.1B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
16.5x
|
| Price / Sales |
7.2x
|
4.8x
|
| Price / FCF |
23.6x
|
20.5x
|
| Revenue Growth YoY |
+10.2%
|
-4.0%
|
| Gross Margin |
71.5%
|
54.2%
|
| Operating Margin |
29.3%
|
23.2%
|
| Return on Equity |
-136.5%
|
37.3%
|
| Dividend Yield |
2.61% |
1.79% |
| FCF Yield |
4.25%
|
4.88%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Qualcomm develops foundational wireless technologies and monetizes them through two main engines: QCT, which supplies Snapdragon application processors and modems, and QTL, which licenses a standards-essential patent portfolio covering CDMA2000, WCDMA, LTE and 5G. The licensing arm and the company's entrenched position in premium Android handsets give it a genuinely high-quality business, evidenc…
Accumulation Zones
| Metric |
ABBV |
QCOM |
| Zone Low |
$194.28 |
$119.56 |
| Zone High |
$220.18 |
$135.51 |
| In Buy Zone? |
No
|
No
|